Actelion Pays €10M for Option to Buy Trophos for up to €195M

Swiss biopharma firm Actelion has announced it will pay French entity Trophos €10 million for an exclusive option to buy the company and acquire its late-stage amyotrophic lateral sclerosis (ALS) drug olesoxime. A Phase III study evaluating the mitochondrial pore modulator is currently underway and is due to report by the end of 2011. Depending on the results of this study, Actelion will have the right to purchase Trophos outright for between €125 million and €195 million in cash, dependent on regulatory approvals and the clinical progress of Trophos’ CNS drug pipeline.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail